Document is current
Any future updates will be listed below
-
Authors
Ham, Kealy R.
Boldt, David W.
McCurdy, Michael T.
Busse, Laurence W.
Favory, Raphael
Gong, Michelle N.
Khanna, Ashish K.
Chock, Stefan N.
Zeng, Feng
Chawla, Lakhmir S.
Tidmarsh, George F.
Ostermann, Marlies
- License Information
-
More Information
Article History
Received: 5 April 2019
Accepted: 20 May 2019
First Online: 3 June 2019
Ethics approval and consent to participate
: The ATHOS-3 study was approved by the appropriate national authorities and local research ethics boards. The study was conducted in accordance with the current Good Clinical Practice Guidelines, applicable local regulations, and ethical principles described in the Declaration of Helsinki.
: Not applicable.
: KRH reports no conflict of interest. DWB received consulting payment from La Jolla Pharmaceutical Company and received grant/payment to his institution from La Jolla Pharmaceutical Company. MTM is on the speakers bureau for La Jolla Pharmaceutical Company, and his institution received a grant for its role as a participating site in the ATHOS-3 trial. LWB reports payment for consulting work from La Jolla Pharmaceutical Company. RF reports nothing to disclose. MNG reports payment to her institution for the conduct of the trials in the form of a contract to perform the study. AKK reports payment from La Jolla Pharmaceutical Company for consulting work and participation in the company’s speakers bureau. SNC reports nothing to disclose. LSC and GFT are employees of La Jolla Pharmaceutical Company. MO and FZ report nothing to disclose.
